Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2024-513911-28-00
Authorised, recruiting Phase III

Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

2024-513911-28-00 · tracked via the Priya Life Science EU tracker
Sponsor
Diamedica Therapeutics Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
25/11/2025
Enrollment target
100
Sites
Romania, Hungary, Belgium, Poland, Spain, France

Condition studied

Acute Ischemic Stroke

Investigational medicinal product(s)

centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulationexcept for the active pharmaceutical ingredient (API).

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Stroke recovery as defined by participants with excellent functional outcomes at Day 90 as assessed via the modified Rankin Score (mRS [dichotomized]), mRS scores of 0 or 1 represent responders, scale range of 0–6., Incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs)., Incidence, severity, and causality of adverse events of special interest (AESI)., Tolerability (incidence and severity of injection site adverse reactions)., Change from Baseline in physical examination (PE) at Day 21 and Day 90., Change from Baseline in vital sign measurements (resting heart rate (HR), systolic/diastolic blood pressure (BP), respiratory rate (RR), and body temperature (BT)) at Days 1, 4, 21, and 90., Change from Baseline in hematology and chemistry parameters at Day 4, Day 21, and Day 90., Change from baseline in 12-lead Electrocardiogram (ECG) at Day 1 and Day 90 as determined by the Investigator.

Endpoint detail

Assessment of effect on disability across the full spectrum of AIS by examining the distribution of mRS (shift) scores (scale range = 0 to 6) at Day 90., Proportion of participants achieving independent function (able to look after their own affairs without assistance) with or without minor disability at Day 90 assessed as mRS 0-2 (dichotomized). mRS scores of 0, 1, or 2 represent responders, scale range of 0–6., Mortality rate as defined by event rate (%) for mortality over 90 days., Proportion of participants achieving an excellent neurological outcome defined by NIHSS = 0-1 (dichotomized) (NIHSS scores of 0 or 1, scale range 0 to 42) at Day 90., Proportion of participants achieving an excellent functional independence in activities of daily living defined by Barthel Index score (dichotomized) greater than or equal to 95 (scale range 0 to 100) at Day 90., Recurrent AIS as defined by proportion of participants who experience a recurrent AIS by Day 90 as assessed by a new, persistent neurological deficit attributable to cerebrovascular ischemia. Imaging findings, if available, should support the diagnosis.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-513911-28-00 on CTIS ↗ ← All trials in the EU